About Syschem India
Syschem India is a publicly listed company based in Chandigarh (India) founded in 1993. Contract manufacturer for APIs and bulk drugs. The company has 115 employees. Its Indian entity Syschem (India) Limited reported revenue of ₹574 Cr. Its focus areas include Biopharma Outsourcing, CDMO, Small Molecules & Peptides and API Production. Similar companies include Laurus Labs, Symbiotec and SeQuent; 2 of its 3 listed similar companies have raised funding.
Company details
Syschem India was founded in 1993 and is based in Chandigarh, India. Operations focus on contract manufacturing of active pharmaceutical ingredients (APIs) and bulk drugs at pilot and commercial scales. Key APIs produced include clopidogrel bisulphate, atorvastatin calcium, fexofenadine HCl, ornidazole, ofloxacin, ciprofloxacin HCl, aceclofenac, diclofenac, nitazoxanide, and silver sulphadiazine. Custom synthesis and purification of specialty solvents are also offered in the pharmaceutical sector.
- Headquarters Chandigarh, India
- Employees 115
- Stage Public
- SectorsHealthcare
- Email••••••••
- Website syschem.in
- Social LinkedIn
- Legal Name Syschem India Ltd.
- Market Cap₹189 Cr
SYSCHEM · BSE
- Share Price₹33.25
-5.70% today
- Revenue₹574 Cr
FY 2025-26 · +48.6% YoY
- EBITDA₹21.10 Cr
Margin 3.7%
- Net Profit₹10.94 Cr
FY 2025-26 · +2331.1% YoY
- P/E (TTM)31.9x
P/B 1.4x
- ROE9.7%
ROCE 14.9%
- Employee Count115
Associated legal entities of Syschem India
Syschem India operates through Syschem (India) Limited, a listed company (active). Its filings, financials, charges and directors are on the company page.
| Legal entity | Status | Incorporated | Registered in | Revenue (FY 2026) | Employees | Directors | Company page |
|---|---|---|---|---|---|---|---|
| Syschem (India) Limited Listed CIN L24219HR1993PLC032195 | Active | 31 Dec 1993 | ₹574 Cr | 110 | 8 | View details |
Board of directors of Syschem (India) Limited (Syschem India)
Syschem (India) Limited is the primary company behind Syschem India. The board of Syschem (India) Limited currently have 6 directors; the longest-serving is Ranjan Jain, appointed in 2015. 23 earlier directors have ceased.
| Director | Designation | Appointed | Tenure | Entity |
|---|---|---|---|---|
| Ranjan Jain DIN 00635274 | Managing Director | 13 Jan 2015 | 11 yrs 9 mo | Syschem (India) Limited |
| Suninder Veer Singh DIN 07693557 | Whole-time director | 30 Dec 2016 | 9 yrs 10 mo | Syschem (India) Limited |
| Arshdeep Kaur DIN 08056826 | Director | 02 Nov 2022 | 3 yrs 11 mo | Syschem (India) Limited |
| Renu Rawat DIN 08161739 | Director | 02 Nov 2022 | 3 yrs 11 mo | Syschem (India) Limited |
| Madan Lal Aggarwal DIN 02403905 | Director | 08 Nov 2024 | 1 yr 11 mo | Syschem (India) Limited |
| Sunil Kumar Bhasin DIN 10996254 | Director | 24 Mar 2025 | 1 yr 7 mo | Syschem (India) Limited |
People of Syschem India
8 people are tracked at Syschem India (3 in leadership, 5 in team); the tracked headcount is 115.
| Name | Role | Group |
|---|---|---|
Rajinder Kumar | Head Of Engineering | Leadership |
Sanjeev Agrawal | CFO | Leadership |
| Director | Leadership | |
S.p. Singh | C.e.o | Team |
Shikha Kataria | Company Secretary | Team |
Company Secretary | Company Secretary And Compliance Officer | Team |
Sanjay Singh | V.p. (operations) | Team |
Kanti Shori | Sr. Manager. Business Development | Team |
Complete people profiles for Syschem India
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
IPO & Listings of Syschem India
Syschem India is a publicly listed company on the BSE with ticker symbol SYSCHEM in India, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
- IPO date04 Sep 2001
- Listed onBSE: 531173
- Listed entitySyschem India Ltd.
- Exchange sectorHealth technology
- ISININE121D01036
- Share price₹36.79 (-0.03% on the day) · 2026-10-14
- Market capitalisation₹197 Cr
- Price to earnings34.1
- EPS (diluted, trailing year)₹1.08
- Volume (last session)3,962
Financials of Syschem India
Exchange-reported figures of Syschem (India) Limited, the listed company behind Syschem India (BSE: SYSCHEM).
Financial Highlights
FY 2025-26 · StandaloneRevenue vs Net Profit ₹ Cr
Margin trends
Financial summary ₹ Cr
| Metrics | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Income statement | |||||||
| Revenue | 574 | 386 | 233 | 130 | 65.63 | 74.41 | 76.93 |
| Revenue growth | +48.6% | +65.4% | +79.1% | +98.7% | -11.8% | -3.3% | - |
| EBITDA | 21.10 | 3.98 | 6.98 | 8.65 | 0.56 | (5.17) | (0.11) |
| EBITDA margin | +3.7% | +1.0% | +3.0% | +6.6% | +0.9% | -7.0% | -0.1% |
| Profit before tax | 14.80 | 1.00 | 4.11 | 6.16 | (2.17) | (7.32) | (2.19) |
| Net profit | 10.94 | 0.45 | 2.76 | 4.52 | (1.70) | (5.29) | (1.81) |
| Net profit margin | +1.9% | +0.1% | +1.2% | +3.5% | -2.6% | -7.1% | -2.4% |
| EPS (₹) | 1.93 | 0.11 | 0.69 | 1.42 | (0.73) | (2.58) | (0.99) |
| Balance sheet | |||||||
| Total assets | 125 | 93.21 | 67.26 | 49.74 | 34.27 | 38.93 | 26.47 |
| Net worth | 122 | 91.28 | 56.95 | 22.30 | 6.94 | 7.12 | 10.01 |
| Total debt | 0.40 | 0.00 | 0.45 | 1.61 | 1.75 | 15.21 | 16.45 |
| Cash & bank | 9.44 | 2.14 | 0.10 | 0.66 | 0.37 | 1.42 | 0.16 |
| Net working capital | 55.62 | 37.38 | 29.58 | 15.59 | (2.00) | 3.90 | (4.87) |
| Cash flow | |||||||
| Cash from operations | 7.59 | (10.09) | (25.65) | (8.49) | 1.07 | 3.72 | 3.46 |
| Cash from investing | (19.57) | (21.67) | (6.46) | (1.65) | (0.78) | (3.77) | (3.62) |
| Cash from financing | 17.95 | 33.81 | 31.64 | 10.69 | (0.28) | (0.06) | (0.02) |
| Particulars | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 113 | 109 | 219 | 142 | 104 | 109 | 119 | 77.76 |
| Revenue growth (YoY) | +9.4% | -0.1% | +84.5% | +82.0% | +118.0% | +24.9% | - | - |
| Other income | 0.00 | 0.05 | 0.00 | 0.00 | 0.01 | 0.01 | 0.02 | 0.02 |
| Total expenses | 109 | 109 | 210 | 136 | 100 | 107 | 117 | 76.56 |
| EBITDA | 4.44 | 0.55 | 9.36 | 5.97 | 3.30 | 2.47 | 1.90 | 1.20 |
| EBITDA margin | +3.9% | +0.5% | +4.3% | +4.2% | +3.2% | +2.3% | +1.6% | +1.5% |
| Depreciation | 1.57 | 1.56 | 1.73 | 0.82 | 0.76 | 0.76 | 0.91 | 0.68 |
| Interest | 0.74 | 0.49 | 2.04 | 0.17 | 0.01 | 0.04 | 0.00 | 0.04 |
| Profit before tax | 2.13 | (1.45) | 5.59 | 4.98 | 2.54 | 1.68 | 1.01 | 0.50 |
| Tax | 0.22 | 0.22 | 3.86 | 0.79 | 0.65 | 0.00 | 0.55 | 0.00 |
Financial Statements
| Particulars | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 113 | 109 | 219 | 142 | 104 | 109 | 119 | 77.76 |
| Revenue growth (YoY) | +9.4% | -0.1% | +84.5% | +82.0% | +118.0% | +24.9% | - | - |
| Other income | 0.00 | 0.05 | 0.00 | 0.00 | 0.01 | 0.01 | 0.02 | 0.02 |
| Total expenses | 109 | 109 | 210 | 136 | 100 | 107 | 117 | 76.56 |
| EBITDA | 4.44 | 0.55 | 9.36 | 5.97 | 3.30 | 2.47 | 1.90 | 1.20 |
| EBITDA margin | +3.9% | +0.5% | +4.3% | +4.2% | +3.2% | +2.3% | +1.6% | +1.5% |
| Depreciation | 1.57 | 1.56 | 1.73 | 0.82 | 0.76 | 0.76 | 0.91 | 0.68 |
| Interest | 0.74 | 0.49 | 2.04 | 0.17 | 0.01 | 0.04 | 0.00 | 0.04 |
| Profit before tax | 2.13 | (1.45) | 5.59 | 4.98 | 2.54 | 1.68 | 1.01 | 0.50 |
| Tax | 0.22 | 0.22 | 3.86 | 0.79 | 0.65 | 0.00 | 0.55 | 0.00 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Revenue | 574 | 386 | 233 | 130 | 65.63 | 74.41 | 76.93 |
| Revenue growth | +48.6% | +65.4% | +79.1% | +98.7% | -11.8% | -3.3% | - |
| Other income | 0.02 | 0.04 | 0.17 | 0.25 | 0.13 | 0.26 | 0.09 |
| Total expenses | 553 | 382 | 226 | 122 | 65.07 | 79.58 | 77.04 |
| Employee cost | 0.00 | 8.25 | 6.08 | 4.40 | 4.54 | 4.10 | 2.99 |
| EBITDA | 21.10 | 3.98 | 6.98 | 8.65 | 0.56 | (5.17) | (0.11) |
| EBITDA margin | +3.7% | +1.0% | +3.0% | +6.6% | +0.9% | -7.0% | -0.1% |
| Depreciation | 4.06 | 2.95 | 2.79 | 2.70 | 2.58 | 2.35 | 2.15 |
| Interest | 2.26 | 0.07 | 0.25 | 0.04 | 0.28 | 0.06 | 0.02 |
| Profit before tax | 14.80 | 1.00 | 4.11 | 6.16 | (2.17) | (7.32) | (2.19) |
| Tax | 3.86 | 0.55 | 1.35 | 1.64 | (0.47) | (1.75) | (0.35) |
| Net profit | 10.94 | 0.45 | 2.76 | 4.52 | (1.70) | (5.29) | (1.81) |
| Net profit margin | +1.9% | +0.1% | +1.2% | +3.5% | -2.6% | -7.1% | -2.4% |
| EPS (₹) | 1.93 | 0.11 | 0.69 | 1.42 | (0.73) | (2.58) | (0.99) |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Equity & liabilities | |||||||
| Share capital | 49.01 | 43.51 | 39.86 | 31.89 | 23.29 | 22.54 | 19.79 |
| Reserves & surplus | 73.42 | 47.77 | 17.09 | (9.59) | (17.24) | (15.54) | (9.97) |
| Shareholders' funds (net worth) | 122 | 91.28 | 56.95 | 22.30 | 6.94 | 7.12 | 10.01 |
| Secured loans | 0.40 | 0.00 | 0.00 | 0.00 | 0.00 | 12.17 | 12.21 |
| Unsecured loans | 0.00 | 0.00 | 0.45 | 1.61 | 1.75 | 3.04 | 4.24 |
| Total debt | 0.40 | 0.00 | 0.45 | 1.61 | 1.75 | 15.21 | 16.45 |
| Total liabilities | 125 | 93.21 | 67.26 | 49.74 | 34.27 | 38.93 | 26.47 |
| Assets | |||||||
| Gross block | 103 | 84.66 | 59.23 | 56.55 | 55.54 | 51.12 | 46.83 |
| Net block | 67.60 | 53.11 | 30.57 | 30.66 | 31.55 | 29.71 | 27.55 |
| Capital work in progress | 0.00 | 0.29 | 4.11 | 0.15 | 0.00 | 0.98 | 0.66 |
| Investments | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Inventories | 58.24 | 68.28 | 51.40 | 15.52 | 19.14 | 33.26 | 20.53 |
| Sundry debtors | 144 | 89.54 | 68.43 | 41.94 | 3.32 | 5.74 | 9.86 |
| Cash & bank balances | 9.44 | 2.14 | 0.10 | 0.66 | 0.37 | 1.42 | 0.16 |
| Loans & advances | 6.40 | 1.48 | 6.42 | 0.45 | 0.71 | 1.72 | 0.56 |
| Total current assets | 219 | 161 | 126 | 58.57 | 23.54 | 42.14 | 31.11 |
| Total current liabilities | 163 | 124 | 96.77 | 42.98 | 25.54 | 38.24 | 35.98 |
| Net working capital | 55.62 | 37.38 | 29.58 | 15.59 | (2.00) | 3.90 | (4.87) |
| Total assets | 125 | 93.21 | 67.26 | 49.74 | 34.27 | 38.93 | 26.47 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Opening cash | 2.14 | 0.10 | 0.57 | 0.03 | 0.02 | 0.14 | 0.32 |
| Net cash from operating activities | 7.59 | (10.09) | (25.65) | (8.49) | 1.07 | 3.72 | 3.46 |
| Net cash from investing activities | (19.57) | (21.67) | (6.46) | (1.65) | (0.78) | (3.77) | (3.62) |
| Net cash from financing activities | 17.95 | 33.81 | 31.64 | 10.69 | (0.28) | (0.06) | (0.02) |
| Net change in cash | 5.97 | 2.04 | (0.48) | 0.54 | 0.00 | (0.11) | (0.18) |
| Closing cash | 9.44 | 2.14 | 0.10 | 0.66 | 0.37 | 1.42 | 0.16 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Growth | |||||||
| Sales growth | +48.6% | +65.4% | +79.1% | +98.7% | -11.8% | -3.3% | - |
| EBITDA growth | +430.2% | -43.0% | -19.3% | +1444.6% | +110.8% | -4600.0% | - |
| PBT growth | +1379.0% | -75.7% | -33.3% | +9998.0% | +70.4% | -234.3% | - |
| Net income growth | +2331.1% | -83.7% | -38.9% | +365.9% | +67.9% | -192.3% | - |
| Revenue CAGR (3Y) | +71.2% | +80.5% | +46.4% | +19.2% | -11.0% | +3.8% | +83.1% |
| EBITDA CAGR (3Y) | +34.6% | +92.3% | - | - | -46.1% | - | +22.4% |
| Profitability & leverage | |||||||
| Net income margin | +1.7% | +0.1% | +1.2% | +3.5% | -2.6% | -7.5% | -2.4% |
| Return on capital employed | +14.9% | +1.2% | +6.1% | +12.7% | 0.0% | 0.0% | 0.0% |
| Return on net worth | +9.7% | +0.5% | +5.3% | +20.9% | 0.0% | 0.0% | 0.0% |
| Debt / equity | 0.00 | 0.00 | 0.03 | 0.11 | 1.21 | 1.85 | 1.41 |
| Long-term debt / equity | 0.00 | 0.00 | 0.03 | 0.11 | 1.02 | 1.54 | 1.21 |
| Interest cover | 13.27 | 6.80 | 5.97 | 0.67 | -13.86 | -0.80 | -0.88 |
| Efficiency & per share | |||||||
| Fixed asset turnover | 6.97 | 5.37 | 4.03 | 2.33 | 1.23 | 1.52 | 1.94 |
| Inventory turnover | 10.35 | 6.45 | 6.98 | 7.52 | 2.50 | 2.77 | 3.98 |
| Debtors turnover | 5.59 | 4.89 | 4.23 | 5.76 | 14.49 | 9.54 | 11.54 |
| EPS (₹) | 2.23 | 0.11 | 0.69 | 1.42 | (0.73) | (2.58) | (0.99) |
| Dividend per share (₹) | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Book value per share (₹) | 24.98 | 20.98 | 14.29 | 6.99 | 2.60 | 2.79 | 4.69 |
Similar companies to Syschem India
Syschem India has 3 listed similar companies in our database, 2 of them funded. They include Laurus Labs, Symbiotec and SeQuent.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| lauruslabs.com | 2005 | Hyderabad, India | $229.73M | 6,035 | Pharmaceutical and biotechnology company | |
| symbiotec.in | 2002 | Indore, India | $61.01M | 1,822 | Non-sterile steroid hormone-based APIs and intermediates are manufactured. | |
| sequent.in | 2002 | Bengaluru, India | APIs are developed and manufactured for therapeutic areas. |
Detailed similar companies of Syschem India
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of Syschem India
The website of Syschem India (syschem.in) receives about 1.4K visits a month.
- Monthly visits1.4K
▼ 31.5% vs previous month
Top companies in Biopharma Outsourcing & Drug Delivery
3 companies that operate in the same segment as Syschem India (Biopharma Outsourcing & Drug Delivery) in India, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Developer of integrated contract research development and manufacturing services | 2007 | Bengaluru, Karnataka, India | USD 35.74 M | USD 226.38 M | 1,820 | |
Pharmaceutical and biotechnology company | 2005 | Hyderabad, Telangana, India | USD 229.73 M | USD 726.15 M | 12,470 | |
India's leading healthcare products distribution platform | 2018 | Mumbai, Maharashtra, India | USD 59.67 M | USD 702.49 M | 4,260 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Syschem India
Complete news archive for Syschem India
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Syschem India
Syschem India was founded in 1993.
Syschem India is headquartered in Chandigarh, India.
Syschem India has 115 employees.
The primary company behind Syschem India, Syschem (India) Limited, reported revenue of ₹574 Cr for FY 2026, up 49% year on year.
Syschem India was founded in 1993 and is based in Chandigarh, India. Operations focus on contract manufacturing of active pharmaceutical ingredients (APIs) and bulk drugs at pilot and commercial scales. Key APIs produced include clopidogrel bisulphate, atorvastatin calcium, fexofenadine HCl, ornidazole, ofloxacin, ciprofloxacin HCl, aceclofenac, diclofenac, nitazoxanide, and silver sulphadiazine. Custom synthesis and purification of specialty solvents are also offered in the pharmaceutical sector.
Syschem India's top competitors include Laurus Labs, Symbiotec and SeQuent.
Yes, Syschem India is publicly traded on BSE under the ticker symbol SYSCHEM.
Syschem India operates through Syschem (India) Limited.
The legal entities of Syschem India currently have 8 directors, including Suninder Veer Singh, Ranjan Jain, Arshdeep Kaur and others.